DelveInsight’s “Bronchiectasis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Bronchiectasis market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Bronchiectasis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bronchiectasis: An Overview
Bronchiectasis is a chronic lung disease characterized by persistent and lifelong widening of the bronchial airways and weakening of the function mucociliary transport mechanism owing to repeated infection contributing to bacterial invasion and mucus pooling throughout the bronchial tree.
Bronchiectasis cannot be cured, but it can be managed by medication, using certain devices, or combining these methods and possibly others. Treatment choices for Bronchiectasis include medications, like, antibiotics such as macrolides, and drugs that affect mucus, e.g., bronchodilators, inhaled corticoids, and help cough the mucus out.
Devices like PEP and IPV are also used as hand-held devices to help break up mucus for the treatment and management of disease indications.
Bronchiectasis Market Key Facts
As per DelveInsight, the Bronchiectasis Market Size was found to be USD 379.6 million in 2020, which is anticipated to increase in the coming years.
In 2020, the total prevalent cases of Bronchiectasis in the United States was found to be 418,200+ cases.
According to Quint et al. (2016), while investigating the changes in prevalence from 2004- 2013 in the United Kingdom, the prevalence of bronchiectasis was found to be 486/100,000 in men, and 566/100,000 in women, with the prevalence highest in patients over 60 years of age. The prevalence was slightly lower in Germany in 2013, with an estimated 67 cases per 100,000, as per Ringshausen (2015).
Bronchiectasis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Bronchiectasis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Bronchiectasis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Bronchiectasis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Bronchiectasis Epidemiology segmented by –
Total Prevalent Cases of Bronchiectasis
Prevalence of Bronchiectasis based on Gender
Prevalence of Bronchiectasis based on Comorbidities
Prevalence of Bronchiectasis based on Age
Bronchiectasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchiectasis market or expected to get launched during the study period. The analysis covers the Bronchiectasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bronchiectasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Bronchiectasis Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/bronchiectasis-market
Bronchiectasis Therapeutics Analysis
The pipeline of Bronchiectasis is quite robust, with many products available in the developmental stage. There are several key players involved in the development of promising products which are anticipated to launch in the market in the coming years.
Some of the key companies in the Bronchiectasis Therapeutics Market include:
Insmed Inc.
AstraZeneca
Novartis Pharmaceuticals
Thirty Respiratory Limited
Kyowa Kirin
RedHill Biopharma Limited
Bronchiectasis Therapies covered in the report include:
Brensocatib/ INS 1007
QBW251
RESP301
RHB-204
Benralizumab
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/bronchiectasis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Bronchiectasis Competitive Intelligence Analysis
4. Bronchiectasis Market Overview at a Glance
5. Bronchiectasis Disease Background and Overview
6. Bronchiectasis Patient Journey
7. Bronchiectasis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Bronchiectasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Bronchiectasis Unmet Needs
10. Key Endpoints of Bronchiectasis Treatment
11. Bronchiectasis Marketed Products
12. Bronchiectasis Emerging Drugs and Latest Therapeutic Advances
13. Bronchiectasis Seven Major Market Analysis
14. Attribute Analysis
15. Bronchiectasis Market Outlook (In US, EU5, and Japan)
16. Bronchiectasis Access and Reimbursement Overview
17. KOL Views on the Bronchiectasis Market
18. Bronchiectasis Market Drivers
19. Bronchiectasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Bronchiectasis Pipeline Insight
DelveInsight’s “Bronchiectasis – Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Bronchiectasis therapeutics landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
